Duodenal infusion of donor feces for recurrent Clostridium difficile.
By E. van Nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, Erwin G. Zoetendal, W. D. de Vos, C. Visser, E. Kuijper, J. Bartelsman, J. Tijssen and 3 more. New England Journal of Medicine, 2013
3,483 citations recorded by the source corpus.
BACKGROUND Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. We studied the effect of duodenal infusion of donor feces in patients with recurrent C. difficile infection. METHODS We randomly assigned patients to receive one of three therapies: an initial vancomycin regimen (500 mg orally four times per day for 4 days), followed by bowel lavage and subsequent infusion of a solution of donor feces through a nasoduodenal tube; a standard vancomycin regimen (500 mg orally four times per day for 14 days); or a standard vancomycin regimen with bowel lavage. The primary end point was the resolution of diarrhea associated with C. difficile infection without relapse after 10 weeks. RESULTS The study was stopped after an interim analysis. Of 16 patients in the infusion group, 13 (81%) had resolution of C. difficile-associated diarrhea after the first infusion. The 3 remaining patients received a second infusion with feces from a different donor, with resolution in 2 patients. Resolution of C. difficile infection occurred in 4 of 13 patients (31%) receiving vancomycin alone and in 3 of 13 patients (23%) receiving vancomycin with bowel lavage (P<0.001 for both comparisons with the infusion group). No significant differences in adverse events among the three study groups were observed except for mild diarrhea and abdominal cramping in the infusion group on the infusion day. After donor-feces infusion, patients showed increased fecal bacterial diversity, similar to that in healthy donors, with an increase in Bacteroidetes species and clostridium clusters IV and XIVa and a decrease in Proteobacteria species. CONCLUSIONS The infusion of donor feces was significantly more effective for the treatment of recurrent C. difficile infection than the use of vancomycin. (Funded by the Netherlands Organization for Health Research and Development and the Netherlands Organization for Scientific Research; Netherlands Trial Register number, NTR1177.).
Subfields: Applied Microbiology and Biotechnology, Food Science, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/247813e9093c48598aabc75b6c1b889b34b097d9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Food Science
- Y. Belkaid
- I. Zilber-Rosenberg
- Rob Knight
- Justin L. Sonnenburg
- Eugene Rosenberg
- Eric G. Pamer
- June L. Round
- O. Harrison
In Infectious Diseases
- Y. Belkaid
- O. Harrison
- C. Petersen
- Y. Taur
- I. Zilber-Rosenberg
- Rob Knight
- Justin L. Sonnenburg
- Eugene Rosenberg
Citations in the corpus
- The gut microbiota and inflammatory bowel disease (2014, neutral): “The results of a randomized study to compare FMT with antibiotics for recurrent Clostridium difficile infection were striking [54].”
- Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. (2015, background): “Fecal microbiota transplantation (FMT) has emerged as a novel approach to altering the colonic microbiome and can successfully treat antibioticresistant Clostridium difficile colitis.(12,13) The concept of FMT has captured the imagination of the public, and this approach is being advocated for a num”
- Mechanisms and consequences of intestinal dysbiosis (2017, background): “difficile infection by infusion with microbiota derived from healthy donors cured more than 90% of cases, whereas the traditional treatment with vancomycin only improved 30% of cases [242].”